Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
Andra Tilgase, Pēteris Alberts(Maxygen (United States)), Linda Brokāne, Romualds Erdmanis, Evija Olmane(Pauls Stradiņš Clinical University Hospital), Jurijs Nazarovs(Pauls Stradiņš Clinical University Hospital), Agnija Rasa
Cited by 14
Related Papers
Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains
|Endocrinology|2003|263
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
|Diabetologia|2002|259
Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1
|Journal of Medicinal Chemistry|2002|211
The advent of oncolytic virotherapy in oncology: The Rigvir® story
|European Journal of Pharmacology|2018|179